EJP18 peptide derived from the juxtamembrane domain of epidermal growth factor receptor represents a novel membrane-active cell-penetrating peptide

Eissa, N.G., Sayers, E.J. ORCID: https://orcid.org/0000-0002-2621-1119, Birch, D., Patel, S.G., Tsai, Y.-H. ORCID: https://orcid.org/0000-0003-0589-5088, Nielsen, H. Mørck and Jones, Arwyn ORCID: https://orcid.org/0000-0003-2781-8905 2020. EJP18 peptide derived from the juxtamembrane domain of epidermal growth factor receptor represents a novel membrane-active cell-penetrating peptide. Biochemical Journal 477 (1) , pp. 45-60. 10.1042/BCJ20190452

PDF - Accepted Post-Print Version Download (1MB)

Abstract

Membrane-active peptides have been extensively studied to probe protein–membrane interactions, to act as antimicrobial agents and cell-penetrating peptides (CPPs) for the delivery of therapeutic agents to cells. Hundreds of membrane-active sequences acting as CPPs have now been described including bioportides that serve as single entity modifiers of cell physiology at the intracellular level. Translation of promising CPPs in pre-clinical studies have, however, been disappointing as only few identified delivery systems have progressed to clinical trials. To search for novel membrane-active peptides a sequence from the EGFR juxtamembrane region was identified (named EJP18), synthesised, and examined in its L- and D-form for its ability to mediate the delivery of a small fluorophore and whole proteins to cancer cell lines. Initial studies identified the peptide as being highly membrane-active causing extensive and rapid plasma membrane reorganisation, blebbing, and toxicity. At lower, non-toxic concentrations the peptides outperformed the well-characterised CPP octaarginine in cellular delivery capacity for a fluorophore or proteins that were associated with the peptide covalently or via ionic interactions. EJP18 thus represents a novel membrane-active peptide that may be used as a naturally derived model for biophysical protein–membrane interactions or for delivery of cargo into cells for therapeutic or diagnostic applications.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Pharmacy Chemistry
Publisher:	Portland Press
ISSN:	0264-6021
Date of First Compliant Deposit:	20 January 2020
Date of Acceptance:	10 December 2019
Last Modified:	03 Nov 2024 21:21
URI:	https://orca.cardiff.ac.uk/id/eprint/128803

Citation Data

Cited 7 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item